| Bioactivity | Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cyclase (gQC) inhibitor with IC50 values of 0.012 0.040 µM, respectively. Glutaminyl Cyclase Inhibitor 6 has the potential for the research of Parkinson’s disease[1]. |
| Target | IC50: 0.012 µM (secretory glutaminyl cyclase (sQC)); 0.040 µM (golgi-resident glutaminyl cyclase (gQC)) |
| In Vivo | Glutaminyl Cyclase Inhibitor 6 (compound BI-43) (10, 25, 40 mg/kg; i.p.; daily for 7 days) shows efficacy in alleviating MPTP (HY-15608)-induced motor dysfunctions across multiple behavioral performance tests[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C27H23N5O3 |
| Molar Mass | 465.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mou J, et al. X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson's Disease Mouse Model. J Med Chem. 2024 May 31. |
Glutaminyl Cyclase Inhibitor 6
CAS: F: C27H23N5O3 W: 465.50
Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cy
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.